AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
Completed · Phase 1/Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788 together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of AEE788 when given together with everolimus and to see how well they work in treating patients with recurrent or relapsed glioblastoma multiforme.
Key facts
- Study ID
- NCT00107237
- Run by
- Novartis Pharmaceuticals
- People needed
- 16
- Starts
- 2003-10-01
- Expected to finish
- 2006-06-01
- Last updated by the study team
- 2013-06-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States
- Duke Univaersity Medical Center — Durham, North Carolina, United States
- MD Anderson Cancer Center/University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.